Gilead Sciences (GILD) EVP Cain Wettan details initial stock, RSU and option holdings

Rhea-AI Filing Summary

Gilead Sciences executive Keeley M. Cain Wettan, EVP Gen Counsel, Legal & Comp, filed an initial ownership report showing direct holdings in Gilead Sciences, Inc. common stock and equity awards as of February 4, 2026. The filing lists 3,944 shares of common stock, restricted stock units covering 5,440 and 11,342 shares, and several non-qualified stock options with exercise prices from $57.92 to $117.21 and expirations between 2032 and 2035. The restricted stock units and options vest over three- or four-year schedules, with portions vesting on the first anniversary of grant and the remainder vesting quarterly or annually until fully vested.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Cain Wettan Keeley M

Role EVP Gen Counsel, Legal & Comp

Type	Security	Shares	Price	Value
holding	Restricted Stock Unit	--	--	--
holding	Restricted Stock Unit	--	--	--
holding	Non-qualified Stock Option (Right to Buy)	--	--	--
holding	Non-qualified Stock Option (Right to Buy)	--	--	--
holding	Non-qualified Stock Option (Right to Buy)	--	--	--
holding	Non-qualified Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 5,440 shares (Direct); Non-qualified Stock Option (Right to Buy) — 3,072 shares (Direct); Common Stock — 3,944 shares (Direct)

Footnotes (1)

1. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance vest 6.25% quarterly thereafter until fully vested. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested. The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance vest 6.25% quarterly thereafter until fully vested.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cain Wettan Keeley M

(Last) (First) (Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/04/2026

3. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Gen Counsel, Legal & Comp

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,944	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	(1)	Common Stock	5,440	(2)	D
Restricted Stock Unit	(3)	(3)	Common Stock	11,342	(2)	D
Non-qualified Stock Option (Right to Buy)	(4)	03/10/2032	Common Stock	3,072	$57.92	D
Non-qualified Stock Option (Right to Buy)	(4)	03/10/2033	Common Stock	4,412	$79.5	D
Non-qualified Stock Option (Right to Buy)	(4)	03/10/2034	Common Stock	6,996	$75.12	D
Non-qualified Stock Option (Right to Buy)	(4)	03/10/2035	Common Stock	5,140	$117.21	D

Explanation of Responses:

1. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance vest 6.25% quarterly thereafter until fully vested.

2. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

3. The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

4. The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Keeley M. Cain Wettan	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Gilead Sciences (GILD) Form 3 for Keeley Cain Wettan report?

It reports Keeley M. Cain Wettan’s initial beneficial ownership in Gilead Sciences. The filing lists directly held common stock, restricted stock units, and non-qualified stock options, along with their vesting schedules, exercise prices, and expiration dates as of February 4, 2026.

How many Gilead Sciences (GILD) common shares does Keeley Cain Wettan directly own?

The Form 3 shows direct ownership of 3,944 shares of Gilead Sciences common stock. This position is separate from any restricted stock units or stock options, which are reported as derivative securities with their own vesting and exercise terms.

What restricted stock units are reported for Keeley Cain Wettan at Gilead Sciences (GILD)?

The filing lists two blocks of restricted stock units covering 5,440 and 11,342 shares of Gilead common stock. Each unit represents the contingent right to receive one share, subject to multi-year vesting schedules based on anniversaries of the grant date.

What stock options does Keeley Cain Wettan hold in Gilead Sciences (GILD)?

The Form 3 reports several non-qualified stock options to buy Gilead common stock, with share amounts of 3,072, 4,412, 6,996, and 5,140. Exercise prices range from $57.92 to $117.21, with expirations between March 2032 and March 2035.

How do Keeley Cain Wettan’s Gilead (GILD) restricted stock units vest?

One grant vests over four years, with 25% on the first anniversary and 6.25% quarterly thereafter. Another vests over three years, with 33.33% vesting on each yearly anniversary until the restricted stock units are fully vested.

What is the vesting schedule for Keeley Cain Wettan’s Gilead (GILD) stock options?

The options vest over four years. For each grant, 25% of the shares vest on the first anniversary of the grant date, and the remaining 75% vest in 6.25% quarterly installments until fully vested, subject to continued service.